Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Salah‐Eddin Al‐Batran"" wg kryterium: Autor


Tytuł :
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV
Autorzy :
Sylvie Lorenzen
Alexander Biederstädt
Ulrich Ronellenfitsch
Christoph Reißfelder
Stefan Mönig
Frederik Wenz
Claudia Pauligk
Martin Walker
Salah-Eddin Al-Batran
Bernhard Haller
Ralf-Dieter Hofheinz
Pokaż więcej
Temat :
Locally advanced adenocarcinoma of the gastroesophageal junction
Neoadjuvant radiochemotherapy
Perioperative chemotherapy
FLOT
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Opis pliku :
electronic resource
Relacje :
http://link.springer.com/article/10.1186/s12885-020-07388-x; https://doaj.org/toc/1471-2407
Dostęp URL :
https://doaj.org/article/25865561bf92448c8e948648ed60c194
Czasopismo naukowe
Tytuł :
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –
Autorzy :
Thorsten O. Goetze
Wolf O. Bechstein
Ulli Simone Bankstahl
Tobias Keck
Alfred Königsrainer
Sven A. Lang
Claudia Pauligk
Pompiliu Piso
Arndt Vogel
Salah-Eddin Al-Batran
Pokaż więcej
Temat :
Gallbladder carcinoma
Biliary tract cancer
Neoadjuvant therapy
Perioperative chemotherapy
Randomized trial
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Opis pliku :
electronic resource
Relacje :
https://doaj.org/toc/1471-2407
Dostęp URL :
https://doaj.org/article/15c20019c50748afabcbc94e973c5ec6
Czasopismo naukowe
Tytuł :
Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score
Autorzy :
Maria R. Gaiser
Sylvie Lorenzen
Kirsten Merx
Jörg Trojan
Janja Ocvirk
Thomas J. Ettrich
SalahEddin AlBatran
Holger Schulz
Nils Homann
Hans‐Peter Feustel
Michael Schatz
Melanie Kripp
Nadine Schulte
Steffen Heeger
Soetkin Vlassak
Winfried Koch
Ralf‐Dieter Hofheinz
Pokaż więcej
Temat :
acneiform skin toxicity
EGFR inhibitor
women
WoMo score
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
Cancer Medicine, Vol 8, Iss 9, Pp 4169-4175 (2019)
Opis pliku :
electronic resource
Relacje :
https://doaj.org/toc/2045-7634
Dostęp URL :
https://doaj.org/article/fff0c41466f24d5cbeb88fb44afecf15
Czasopismo naukowe
Tytuł :
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review
Autorzy :
Elena Gabriela Chiorean
Winson Y. Cheung
Guido Giordano
George Kim
Salah-Eddin Al-Batran
Pokaż więcej
Temat :
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Opis pliku :
electronic resource
Relacje :
https://doaj.org/toc/1758-8359
Dostęp URL :
https://doaj.org/article/ee73b889a31f4dfcb939c37dae0cffaa
Czasopismo naukowe
Tytuł :
Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma.
Autorzy :
Christine Koch
Cornelius Reitz
Teresa Schreckenbach
Katrin Eichler
Natalie Filmann
Salah-Eddin Al-Batran
Thorsten Götze
Stefan Zeuzem
Wolf Otto Bechstein
Thomas Kraus
Jörg Bojunga
Markus Düx
Jörg Trojan
Irina Blumenstein
Pokaż więcej
Temat :
Medicine
Science
Źródło :
PLoS ONE, Vol 14, Iss 10, p e0223613 (2019)
Opis pliku :
electronic resource
Relacje :
https://doaj.org/toc/1932-6203
Dostęp URL :
https://doaj.org/article/0ce05c5c91764181999f73edd0feb191
Czasopismo naukowe
Tytuł :
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
Autorzy :
Salah-Eddin Al-Batran
Thorsten O. Goetze
Daniel W. Mueller
Arndt Vogel
Michael Winkler
Sylvie Lorenzen
Alexander Novotny
Claudia Pauligk
Nils Homann
Thomas Jungbluth
Christoph Reissfelder
Karel Caca
Steffen Retter
Eva Horndasch
Julia Gumpp
Claus Bolling
Karl-Hermann Fuchs
Wolfgang Blau
Winfried Padberg
Michael Pohl
Andreas Wunsch
Patrick Michl
Frank Mannes
Matthias Schwarzbach
Harald Schmalenberg
Michael Hohaus
Christian Scholz
Christoph Benckert
Jorge Riera Knorrenschild
Veit Kanngießer
Thomas Zander
Hakan Alakus
Ralf-Dieter Hofheinz
Claus Roedel
Manish A. Shah
Mitsuru Sasako
Dietmar Lorenz
Jakob Izbicki
Wolf O. Bechstein
Hauke Lang
Stefan P. Moenig
Pokaż więcej
Temat :
Oligometastatic cancer
Metastatic gastric cancer
Metastatic gastroesophageal junction cancer
Limited-metastatic disease
Localized peritoneal carcinomatosis
Perioperative chemotherapy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
BMC Cancer, Vol 17, Iss 1, Pp 1-7 (2017)
Opis pliku :
electronic resource
Relacje :
http://link.springer.com/article/10.1186/s12885-017-3918-9; https://doaj.org/toc/1471-2407
Dostęp URL :
https://doaj.org/article/5dc6e803a3084cd49c26c2fd2d3bd2f4
Czasopismo naukowe
Tytuł :
P-0056 - Impact of Age on the Feasibility and Efficacy of Neoadjuvant Chemotherapy in Patients with Locally Advanced Gastroesophageal Cancer: A Retrospective Pooled Analysis of Individual Patient Data
Autorzy :
Sylvie, Lorenzen
Pokaż więcej
Źródło :
In ESMO 16th World Congress on Gastrointestinal Cancer 25-28 June 2014 Barcelona, Spain, Annals of Oncology June 2014 25 Supplement 2:ii31-ii31
Czasopismo naukowe
Tytuł :
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Autorzy :
Joensuu H; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany. heikki.joensuu@hus.
Eriksson M; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Sundby Hall K; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Reichardt A; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Hartmann JT; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Pink D; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Ramadori G; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Hohenberger P; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Al-Batran SE; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Schlemmer M; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Bauer S; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Wardelmann E; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Nilsson B; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Sihto H; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Bono P; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Kallio R; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Junnila J; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Alvegård T; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Reichardt P; Heikki Joensuu and Petri Bono, Comprehensive Cancer Center Helsinki; Heikki Joensuu, Harri Sihto, and Petri Bono, University of Helsinki, Helsinki; Raija Kallio, Oulu University Hospital, Oulu; Jouni Junnila, 4Pharma, Turku, Finland; Mikael Eriksson and Thor Alvegård, Lund University, Lund; Bengt Nilsson, Sahlgrenska University Hospital, Gothenburg, Sweden; Kirsten Sundby Hall, Oslo University Hospital, Oslo, Norway; Annette Reichardt, Daniel Pink, and Peter Reichardt, Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin; Jörg T. Hartmann, Franziskus Hospital, Catholic Hospital Consortium Ostwestfalen, Bielefeld; Giuliano Ramadori, University of Göttingen, Göttingen; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Salah-Eddin Al-Batran, Klinik für Onkologie und Hämatologie am Krankenhaus Nordwest, Frankfurt; Marcus Schlemmer, University Hospital Großhadern, Ludwig Maximilians University, Munich; Sebastian Bauer, Sarcoma Center, West German Cancer Center, Essen; and Eva Wardelmann, Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Münster, Germany.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Jan 20; Vol. 34 (3), pp. 244-50. Date of Electronic Publication: 2015 Nov 02.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Gastrointestinal Neoplasms/*drug therapy
Gastrointestinal Stromal Tumors/*drug therapy
Imatinib Mesylate/*administration & dosage
Administration, Oral ; Aged ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Gastrointestinal Neoplasms/surgery ; Gastrointestinal Stromal Tumors/surgery ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Autorzy :
Modest DP; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Stintzing S; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
von Weikersthal LF; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Decker T; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Kiani A; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Vehling-Kaiser U; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Al-Batran SE; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Heintges T; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Lerchenmüller C; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Kahl C; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Seipelt G; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Kullmann F; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Stauch M; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Scheithauer W; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Held S; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Möhler M; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Jung A; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Kirchner T; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria.
Heinemann V; Dominik P. Modest, Sebastian Stintzing, and Volker Heinemann, University Hospital Grosshadern; Andreas Jung and Thomas Kirchner, University of Munich, Munich; Dominik P. Modest, Sebastian Stintzing, Volker Heinemann, Andreas Jung, and Thomas Kirchner, German Cancer Consortium and German Cancer Research Centre, Heidelberg; Ludwig Fischer von Weikersthal, Gesundheitszentrum St Marien, Amberg; Thomas Decker, Oncological Practice, Ravensburg; Alexander Kiani, Klinikum Bayreuth, Bayreuth; Ursula Vehling-Kaiser, Oncological Practice, Landshut; Salah-Eddin Al-Batran, Krankenhaus Nordwest, Frankfurt am Main; Tobias Heintges, Städtisches Klinikum Neuss, Neuss; Christian Lerchenmüller, Oncological Practice, Münster; Christoph Kahl, Staedtisches Klinikum Magdeburg, Magdeburg; Gernot Seipelt, Oncological Practice, Bad Soden; Frank Kullmann, Klinikum Weiden, Weiden; Martina Stauch, Oncological Practice, Kronach; Svantje Held, ClinAssess, Leverkusen; Markus Möhler, Johannes-Gutenberg Universität and German Cancer Consortium, Mainz, Germany; and Werner Scheithauer, Medical University Vienna, Vienna, Austria. .
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2015 Nov 10; Vol. 33 (32), pp. 3718-26. Date of Electronic Publication: 2015 Aug 10.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*drug therapy
Proto-Oncogene Proteins/*genetics
ras Proteins/*genetics
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bevacizumab/administration & dosage ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Cetuximab/administration & dosage ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Disease-Free Survival ; Female ; Fluorouracil/administration & dosage ; Humans ; Kaplan-Meier Estimate ; Leucovorin/administration & dosage ; Male ; Middle Aged ; Proto-Oncogene Proteins p21(ras) ; Treatment Outcome
SCR Protocol :
IFL protocol
Czasopismo naukowe
Tytuł :
Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Autorzy :
Hofheinz RD; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany .
Gencer D; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Schulz H; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Stahl M; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Hegewisch-Becker S; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Loeffler LM; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Kronawitter U; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Bolz G; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Potenberg J; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Tauchert F; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Al-Batran SE; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Schneeweiss A; Ralf-Dieter Hofheinz and Deniz Gencer, University Hospital Mannheim, Mannheim; Holger Schulz, Praxis Internistische Onkologie und Hämatologie, Frechen; Michael Stahl, Kliniken Essen-Mitte, Essen; Susanna Hegewisch-Becker, Hämatologisch-Onkologische Praxis Eppendorf, Hamburg; Luisa Mantovani Loeffler, Onkologie, Haematologie und Palliativmedizin, Leipzig; Ursula Kronawitter, Onkologische Schwerpunktpraxis, Traunstein; Georg Bolz, Medizinische Klinik I, Ludwigshafen; Jochem Potenberg, Waldkrankenhaus Spandau, Berlin; Felix Tauchert and Salah-Eddin Al-Batran, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main; and Andreas Schneeweiss, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2015 Aug 01; Vol. 33 (22), pp. 2444-9. Date of Electronic Publication: 2015 Jun 29.
Typ publikacji :
Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Quality of Life*
Antimetabolites, Antineoplastic/*adverse effects
Antioxidants/*administration & dosage
Deoxycytidine/*analogs & derivatives
Fluorouracil/*analogs & derivatives
Hand-Foot Syndrome/*prevention & control
Keratolytic Agents/*administration & dosage
Primary Prevention/*methods
Urea/*administration & dosage
Administration, Cutaneous ; Adult ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Breast Neoplasms/drug therapy ; Capecitabine ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Drug Administration Schedule ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Gastrointestinal Neoplasms/drug therapy ; Germany ; Hand-Foot Syndrome/etiology ; Hand-Foot Syndrome/pathology ; Humans ; Incidence ; Male ; Middle Aged ; Ointments ; Severity of Illness Index ; Skin Cream ; Surveys and Questionnaires ; Time Factors ; Treatment Failure
Czasopismo naukowe
Tytuł :
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
Autorzy :
Ohtsu A; Atsushi Ohtsu, National Cancer Center Hospital East, Kashiwa; Keisho Chin, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo; Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan; Jaffer A. Ajani, University of Texas MD Anderson Cancer Center, Houston, TX; Tarek Sahmoud, Heind Smith, Syed Rizvi, David Lebwohl, Novartis Pharmaceuticals, Florham Park, NJ; Yu-Xian Bai, Tumor Hospital of Harbin Medical University, Harbin; Hong-Ming Pan, Sir Run Run Shaw Hospital, Zhejiang; Lin Shen, Peking University Cancer Hospital, Beijing, People's Republic of China; Yung-Jue Bang, Seoul National University College of Medicine; Hyun-Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine; Yeul Hong Kim, Korea University Anam Hospital, Seoul, South Korea; Kun-Huei Yeh, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; David Ferry, New Cross Hospital, Wolverhampton, United Kingdom; Niall C. Tebbutt, Austin Health, Heidelberg, Australia; Salah-Eddin Al-Batran, Institute for Clinical Oncology Research, Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt, Germany; Chiara Costantini, Novartis Pharma AG, Basel, Switzerland; Eric Van Cutsem, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Ajani JA
Bai YX
Bang YJ
Chung HC
Pan HM
Sahmoud T
Shen L
Yeh KH
Chin K
Muro K
Kim YH
Ferry D
Tebbutt NC
Al-Batran SE
Smith H
Costantini C
Rizvi S
Lebwohl D
Van Cutsem E
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 Nov 01; Vol. 31 (31), pp. 3935-43. Date of Electronic Publication: 2013 Sep 16.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Immunosuppressive Agents/*therapeutic use
Sirolimus/*analogs & derivatives
Stomach Neoplasms/*drug therapy
Adenocarcinoma/mortality ; Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Double-Blind Method ; Everolimus ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Proportional Hazards Models ; Sirolimus/therapeutic use ; Stomach Neoplasms/mortality ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies